If you have been reading about immunomodulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Reconstituted before use |
| Typical storage | 2-8 °C, protected from light | Applies to the powder |
| Reconstitution solvent | Sterile water or saline | Follow product labeling |
| Solution stability | Shorter than the powder | Refrigerate and use promptly |
| Primary purity method | Reversed-phase HPLC | Detects related substances |
== History == The safety and effectiveness of donislecel was evaluated in two non-randomized, single-arm studies in which a total of 30 participants with type 1 diabetes and hypoglycemic unawareness received at least one infusion and a maximum of three infusions. Overall, 21 participants did not need to take insulin for a year or more, with eleven participants not needing insulin for one to five years and ten participants not needing insulin for more than five years. Five participants did not achieve any days of insulin independence. The FDA granted marketing approval of Lantidra to CellTrans, Inc.
The history of ethanol as a fuel spans several centuries and is marked by a series of significant milestones. Samuel Morey, an American inventor, was the first to produce ethanol by fermenting corn in 1826. However, it was not until the California Gold Rush in the 1850s that ethanol was first used as a fuel in the United States. Rudolf Diesel demonstrated his engine, which could run on vegetable oils and ethanol, in 1895, but the widespread use of petroleum-based diesel engines made ethanol less popular as a fuel. In the 1970s, the oil crisis reignited interest in ethanol, and Brazil became a leader in ethanol production and use. The United States began producing ethanol on a large scale in the 1980s and 1990s as a fuel additive to gasoline, due to government regulations. Today, ethanol continues to be explored as a sustainable and renewable fuel source, with researchers developing new technologies and biomass sources for its production.
NHK, JVC and Ikegami Tsushinki researchers built an early UHDTV prototype, Super Hi‑Vision, which they demonstrated in January 2003. They used an array of 16 HDTV recorders with a total capacity of almost 3.5 TB that could capture up to 18 minutes of test footage. The camera itself was built with four 2.5-inch (64 mm) CCD image sensors, each with a resolution of 3840 × 2048 (4K resolution). Using two CCDs for green and one each for red and blue, they then used a spatial pixel offset method to bring it to 7680 × 4320 (8K resolution). Subsequently, NHK built an improved and more compact system using CMOS image sensor technology and the CMOS image sensor system was demonstrated at Expo 2005, Aichi, Japan, the NAB 2006 and NAB 2007 conferences, Las Vegas, at IBC 2006 and IBC 2008, Amsterdam, Netherlands, and CES 2009. A review of the NAB 2006 demo was published in a broadcast engineering e-newsletter. Individuals at NHK and elsewhere projected that the timeframe for UHDTV to be available in domestic homes varied between 2015 and 2020 but Japan was to get it in the 2016 time frame.
It is accepted practice to assume that if any symptom typical of DCS is present, that the diver has DCS and will be treated accordingly with recompression. Limited case data suggest that recompression does not usually cause harm if the differential diagnosis between IEBt vs IEDCS is doubtful.
Sources: en.wikipedia.org
was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc." The maneuver was an attempt to avoid a "change-of-control" in order to preserve Schering-Plough's rights to market Remicade. A settlement with Johnson & Johnson was reached in 2011, in which Merck agreed to pay $500 million. Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent. Richard Clark retired as CEO and company president in October 2011 and Kenneth Frazier became CEO. In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce. By 2014, research performed at Merck has led to U.S. FDA approval of 63 new molecular entities. In August 2014, Merck acquired Idenix Pharmaceuticals for $3.85 billion. In September 2014, the US Food and Drug Administration (FDA) approved Pembrolizumab (MK-3475) as a breakthrough therapy for melanoma treatment. In clinical trials, pembrolizumab provided partial tumor regression in about one quarter of patients, many of whom have not seen further progression of their disease in over 6 months of follow-up. In December 2014, the company acquired Swiss biotechnology company OncoEthix for up to $375 million. Between 2010 and 2015, the company cut around 36,450 jobs. During that time, the company sold its consumer health business to Bayer and narrowed the company's focus to immunology, vaccines, diabetes, emerging markets and medicines used in hospitals, like certain antibiotics.
=== Signaling networks === Elucidating complex signaling pathway phosphorylation events can be difficult. In cellular signaling pathways, protein A phosphorylates protein B, and B phosphorylates C. However, in another signaling pathway, protein D phosphorylates A, or phosphorylates protein C. Global approaches such as phosphoproteomics, the study of phosphorylated proteins, which is a sub-branch of proteomics, combined with mass spectrometry-based proteomics, have been utilised to identify and quantify dynamic changes in phosphorylated proteins over time. These techniques are becoming increasingly important for the systematic analysis of complex phosphorylation networks. They have been successfully used to identify dynamic changes in the phosphorylation status of more than 6,000 sites after stimulation with epidermal growth factor. Another approach for understanding Phosphorylation Network is by measuring the genetic interactions between multiple phosphorylating proteins and their targets. This reveals interesting recurring patterns of interactions – network motifs. Computational methods have been developed to model phosphorylation networks and predict their responses under different perturbations.
The studies and plans for the TTC's proposed "desperately needed extension known as the Relief Line", had begun in the late 2010s. By early 2019, the planning for the Relief Line was "well underway and construction was scheduled to begin in 2020, with projected completion in 2029." In April 2019, Ford put the Relief Line project on hold in favour of the Ontario Line, which would use a different route with significant lengths of at-grade or elevated track. On September 25, 2024, Ford promised to build a traffic tunnel under the Highway 401 to relieve congestion, and campaigned on constructing the Bradford Bypass. On October 21, 2024, Ford tabled a bill, titled the Reducing Gridlock, Saving You Time Act, granting the province authority to remove bike lanes from several arterial roads in Toronto, as well as expedite the construction of Highway 413. The bill would also require municipalities to get provincial approval before replacing any automotive lanes with bike lanes. Toronto City Council formally opposed the plan, citing an estimated cost of $48 million to remove the bike lanes on Bloor, Avenue, and Yonge. On November 21, Ford's government made several amendments to the bill which the opposition claimed would protect the province from liability if a cyclist were injured or killed due to the removal of the lanes. The bill passed on November 25, 2024. Ford's bill has faced opposition from local politicians and cycling advocates on grounds of provincial overreach and potential safety impacts to cyclists.
Sources: en.wikipedia.org
The second step in the formation of SCOBY is the introduction of different bacteria into the liquid culture to convert the ethanol product of fermentation into organic acids such as acetic acid, which is a type of ethanol metabolism (lactic acid bacteria may also be added, producing lactic acid from lactic acid fermentation on sugars). A possible byproduct of this reaction is cellulose, which serves as the foundation for the SCOBY biofilm. Like yeasts, the species of bacteria chosen as well as culture conditions directly affect both the characteristics of the liquid kombucha product as well as the composition and morphology of the SCOBY pellicle. While there are many species that have the mechanisms necessary to form cellulose such as Acetobacter and Komagataeibacter, Gluconaceobacter are one of the most populous used, residing in 86–99% of both liquid and biofilm cultures. The necessary culturing conditions of these bacteria are similar to that of yeasts, but require more oxygen due to their aerobic nature in oxidizing ethanol to form organic acids. Once the internal conditions of the co-culture are in place, the symbiotic mixture is left to ferment. Certain studies have claimed optimal fermentation time to be 10 days, but the duration can be modified to change the contents of the yield; greater fermentation times correlate with higher levels of organic acids and other amino acids, which can attribute to the sour undertones of some Kombucha.
=== Extraction thimbles === Extraction thimbles are rod-shape filter paper often used in soxhlet extractors or atomized extractors. It is ideal for very sensitive detection, the performance depends on the thickness of inner diameter. Also, it is usually used in areas of food control and environmental monitoring.
== Overview == The series centers on the humorous adventures of a group of five school-aged kids who are all members of a rock band called "Mulligan Stew" (also referred to as the "Stews" or the "Mulligan Stew Force"). The band members are:
Sources: en.wikipedia.org
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.
Reversed-phase HPLC is the primary tool for purity, paired with mass spectrometry for identity. Amino acid analysis and peptide mapping add sequence confirmation. Several techniques are combined because no single test covers every attribute.
It lacks sulfur-containing residues, so oxidation is limited. Aspartate isomerization and slow hydrolysis are the main concerns. Solution stability is shorter than that of the lyophilized powder.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.